SEZ6L2: A Potential Drug Target and Biomarker for Seizure (G26470)

Target Name: SEZ6L2

NCBI ID: G26470

SEZ6L2

SEZ6L2: A Potential Drug Target and Biomarker for Seizure

Seizure is a life-threatening neurological disorder that affects millions of people worldwide, causing recurrent and often disabling episodes of intense contractions of the brain's electrical activity. Despite advances in treating seizures, the availability of effective medications remains limited, and the disease remains a significant public health burden. The identification of potential drug targets and biomarkers for seizure disorders could lead to the development of more targeted and effective treatments. One such protein, SEZ6L2, has recently emerged as a promising drug target and biomarker for seizure disorders.

SEZ6L2: Structure and Function

SEZ6L2 is a protein that is expressed in a variety of tissues, including brain, heart, and muscle. It is a member of the P2XR family, which includes several related proteins that play a role in modulating pain, inflammation, and neurotransmission. The P2XR family is known for its ability to activate pain receptors and induce neuroinflammation, suggesting that SEZ6L2 may also have seizure-related functions.

SEZ6L2 is expressed in the brain and has been shown to localize to several regions, including the prefrontal cortex, basal ganglia, and cerebellum. It has also been shown to interact with several other proteins, including the neurotransmitter GABA and the ion channel Ca2+. These interactions suggest that SEZ6L2 may play a role in modulating neurotransmission and neural activity.

SEZ6L2 has been shown to be involved in several seizure-related functions. It has been shown to contribute to the development of epileptic seizures, as well as to the worsening of certain types of epilepsy. In addition, SEZ6L2 has been shown to play a role in the regulation of brain activity, as well as in the modulation of pain and inflammation.

SEZ6L2 as a Drug Target

The identification of SEZ6L2 as a potential drug target has led to a growing interest in developing compounds that can modulate its activity. Several studies have shown that SEZ6L2 can be modulated by a variety of drugs, including small molecules, peptides, and antibodies.

One of the most promising approaches to modulating SEZ6L2 is the use of small molecules that can bind to its active site. Small molecules that have been shown to interact with SEZ6L2 include inhibitors of ion channels, such as amikalide, and modulators of pain perception, such as naloxone and baclofen. In addition, several natural compounds, including herbal extracts and essential oils, have also been shown to interact with SEZ6L2.

Another approach to modulating SEZ6L2 is the use of antibodies that can bind to its surface. Preclinical studies have shown that antibodies against SEZ6L2 have the potential to selectively target the protein and modulate its activity. The development of such antibodies could provide a new tool for studying the role of SEZ6L2 in seizure disorders.

SEZ6L2 as a Biomarker

SEZ6L2 has also been shown to be a potential biomarker for seizure disorders. The detection of SEZ6L2 in brain tissue has been shown to be sensitive and specific for the diagnosis of epilepsy, as well as for the assessment of the severity and type of epilepsy. In addition, the levels of SEZ6L2 have been shown to be elevated in the brains of individuals with certain types of epilepsy, and to be reduced in individuals who are not affected by epilepsy.

The potential use of SEZ6L2 as a biomarker for seizure disorders is further enhanced by the fact that the protein is highly conserved across species and has been shown to be expressed in a variety of tissues, including brain, heart, and muscle. This suggests that the detection of SEZ6L2 in these tissues may be a useful

Protein Name: Seizure Related 6 Homolog Like 2

Functions: May contribute to specialized endoplasmic reticulum functions in neurons

The "SEZ6L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEZ6L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets